Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues

Author： Arun B.   Frenkel E.P.  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.3, 2001-03, pp. : 491-505

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan

By  

Current Cancer Drug Targets, Vol. 2, Iss. 2, 2002-06 ,pp. : 103-123

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Taq DNA Polymerase and Human Topoisomerase I by Resveratrol Derivatives

By  

Current Bioactive Compounds, Vol. 14, Iss. 4, 2018-12 ,pp. : 461-466

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of NF-&kgr;B and Proteasome Activity in Tumors: Can We Improve the Therapeutic Potential of Topoisomerase I and Topoisomerase II Poisons

By  

Current Pharmaceutical Design, Vol. 8, Iss. 22, 2002-10 ,pp. : 1945-1958

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacologic Inhibition of Platelet Function: Correlation between In Vitro Tests of Platelet Function and Clinical Outcomes

By Ashley Kellan E.   Lincoff A. Michael  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 5, 2008-01 ,pp. : 283-295

Adis International

Access to resources Recommend Favorite

Sorafenib: a clinical and pharmacologic review

By Iyer Renuka   Fetterly Gerald   Lugade Amit   Thanavala Yasmin  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1943-1955

Informa Healthcare

Access to resources Recommend Favorite